Camras Vision Inc., a North Carolina-based ophthalmic medical device company, has raised over $3 million in a private stock offering, according to a filing Tuesday with the Securities and Exchange Commission.

The company filed the Form D on Nov. 28 and declined to disclose what it intended to do with the funds. The total worth of shares sold was $3,003,391. The company has nearly $4 million worth of shares remaining.

Camras Vision created the Camras device to avoid complications following the glaucoma surgery and will provide ophthalmologists with the first tool that can stop the progression of glaucoma. The device can successfully drain aqueous humor externally, avoiding the scarring that is associated with all other incisional/shunt surgeries.

Glaucoma is the leading cause of irreversible blindness worldwide, affecting 4 million Americans and around 80 million persons worldwide by 2020.

The company is led by CEO Ray Krauss and President Roberto Alfaro. Krauss has over 30 years of executive experience in the medical device industry as he led operations for Summit Technology to bring PRK/LASIK to the market. Alfaro previously worked at Deloitte.

Companies relying on a Reg D exemption do not have to register their offering of securities with the SEC, but they must file what’s known as a Form D electronically with the SEC after they first sell their securities.

The filing can be found here.